

TRANSITIONS

A NEWSLETTER FOR EQUITY HOLDERS OF TRT

Vol. 36 / May 2016

Woodstock, GA



(Above) *The new office in bloom.*

Dr. Tom Lue Forms New Company to License TRT Technology

Tissue Regeneration Technologies, LLC (TRT) announces an Exclusive License Agreement with Acoustic Wave Cell Therapy, Inc. (AWCT), whereby AWCT will utilize TRT's extensive patent portfolio to develop and market low energy acoustic wave treatments for multiple internal organs and associated tissues and pathologies.

AWCT's founder and Chief Medical Officer is Dr. Tom Lue, a renowned researcher and clinician, and Professor of Urology at the University of California San Francisco (UCSF) for over 30

years. UCSF is home to one of the world's premier medical centers and is the leading public recipient of biomedical research grants from the National Institutes of Health. Five of its researchers have received the Nobel Prize in Medicine and Physiology. Dr. Lue and his research team have spent the last five years working with TRT technology at UCSF to develop optimized protocols to treat different tissue types and organs in preclinical studies. In their UCSF research laboratory, they have successfully regenerated damaged tissues in various organs in animals and established the safety of their protocols.

AWCT has obtained from UCSF an exclusive license to the patent rights associated with Dr. Lue's discoveries. AWCT will now take over the clinical development and do all work necessary to obtain FDA approval for these treatments. Therapeutic targets include diseases of the liver, kidney, urinary tract and pancreas. Possible early projects include reversing cirrhosis and greatly reducing the need for dialysis. TRT will obtain ownership in AWCT and a Royalty as well as their organizational support. This is an amazing development. I hope this will soon lead to the last utterance of **"THIS IS TOO GOOD TO BE TRUE!"**

Last Call for \$.50 Shares!

Management has decided to close the current \$.50 share offering, and raise the pricing to \$1.00 per share. This is based on the increased demand associated with many recent positive developments. **The new pricing will begin May 15, 2016.** Please contact me immediately if you want to participate in current pricing.

Contact Us

Tissue Regeneration Technologies, LLC

251 Heritage Walk

Woodstock, GA 30188

(404) 402-6844

Email: info@trtllc.com

Website: www.trtllc.com

Latest Discoveries and New Treatment Protocols

Over the last year we have developed a strong relationship with Dr. Ken Craig from New Zealand. He operates our devices both at home and in Australia and the Middle East where he has active practices and partners. His specialty is Sports Medicine and he treats many high level and professional athletes. He just returned from London where his shockwave paper was awarded for excellence by the FIFA Congress (International Football Federation). Most importantly, with Ken, we filed for a patent for his Optimization protocol whereby you make athletes **BETTER**, **STRONGER**, and **FASTER** and help prevent injuries. We also help reverse the symptoms associated with aging: lack of strength and balance. Go to the TRT Facebook page to see several testimonials. We also discovered and patented that by treating major muscle groups over time, you can drastically reduce blood sugar levels! Amazing!

Congratulations Dr. Schaden

Our Founder, Friend, and Medical director was recently appointed as Co-Director of the Austrian Workman's Compensation Organization and will help shape their policies and research. This organization is responsible for insuring over 20% of the lives in Austria and was the earliest adopter of shockwaves as the standard of care for numerous pathologies. This appointment is well deserved and will lead to further research into the science of this amazing technology. Congratulations!



Dr. Schaden with NBA star Carlos Delfino.

This newsletter is not an offer to sell or solicitation of an offer to buy TRT securities. Investment decisions should be based on the risks and disclosures presented in TRT's Confidential Memorandum. This newsletter contains forward looking statements within the meaning of the federal securities laws. Forward looking statements are only predictions and not guarantees of performance. You should not place undue reliance on any forward-looking statements.

Latest Research Projects and Developments

Cancer studies have initiated in Austria at the University of Linz under the guidance of Dr. Patrick Paulus. We hope to report his early findings soon.

At the University of Innsbruck, the first patient suffering from paralysis after cardiothoracic surgery has been treated with very promising early results. This is after the outstanding publication in the Journal of The American Heart Association whereas animals were quite successfully treated to reverse paralysis. More than 10% of patients who undergo high level heart surgery, whereby they are placed on a bypass pump to stop the beating heart, suffer from permanent paralysis. We have shown that if treated early after paralysis we can reverse the paralysis in the majority of cases.

At the recent bi-annual ISMST Research Meeting in Vienna, 16 research presentations were made by physicians from around the world. More than 30 countries were represented. Of the 16 presentations, 14 utilized TRT technology. Only Dr. Wang from Taiwan presented a paper from another manufacturer. We are not yet approved in Taiwan, but with the help of MTS that should change soon and Dr. Wang has expressed his interest in working with us. The most interesting paper suggests that episomes, loaded with RNA, will play a critical role in future research.